OKYO Pharma Limited (OKYO)
| Market Cap | 85.54M +71.6% |
| Revenue (ttm) | n/a |
| Net Income | -4.61M |
| EPS | -0.11 |
| Shares Out | 52.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,284 |
| Open | 1.630 |
| Previous Close | 1.680 |
| Day's Range | 1.630 - 1.699 |
| 52-Week Range | 1.440 - 3.349 |
| Beta | -0.05 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+452.15%) |
| Earnings Date | Jul 18, 2025 |
About OKYO
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited wa... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for OKYO stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 452.15% from the latest price.
News
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO's introduction to the broader ophthalmology community at ASCRS ...
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa...
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa...
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa...
Okyo Pharma director John Brancaccio acquires 5,000 shares
OKYO Pharma (OKYO) has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.
OKYO Pharma Announces Director Acquires Shares
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa...
Okyo Pharma CDO, director acquire shares
OKYO Pharma (OKYO) announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his…
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa...
Okyo Pharma reports results from Phase 2a trial of urcosimod
OKYO Pharma (OKYO) announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod for the treatment of NCP. This new…
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa...
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma initiated with an Overweight at Piper Sandler
Piper Sandler analyst Biren Amin initiated coverage of Okyo Pharma (OKYO) with an Overweight rating and $7 price target The firm is positive on the company’s lead asset, urcosimod, for…
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
Piper Sandler is acting as sole book running manager for the offering.
Okyo Pharma announces ordinary shares offering, no amount given
Okyo Pharma (OKYO) Limited announced that it intends to offer to sell its ordinary shares in an underwritten public offering. All of the ordinary shares are to be sold by…
OKYO Pharma Announces Public Offering of Ordinary Shares
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma appoints Mantelli as Chief Medical Officer
OKYO Pharma (OKYO) announced the appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer. Dr. Mantelli led the clinical development, regulatory approval, and global medical strategy of Oxerva...
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease Dr. Mantelli...
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod
OKYO Pharma (OKYO) held a Type C meeting with the Food & Drug Administration regarding the Phase 2b/3 human clinical trial of urcosimod for the treatment of neuropathic corneal pain.
OKYO Pharma Announces Successful Type C Meeting with the FDA
LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo announces FDA authorized single-patient expanded IND for urcosimod
OKYO Pharma (OKYO) announced that the U.S. Food and Drug Administration, FDA, has authorized a single-patient expanded access Investigational New Drug, IND, application submitted by Pedram Hamrah, MD,...
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma appoints Robery Dempsey as CEO
OKYO Pharma (OKYO) announced that, effective immediately, Robert Dempsey will assume the role of CEO. Gary Jacob, Ph.D. will transition to Chief Development Officer and continue to serve as a…